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Hypofractionated conformal radiotherapy in combination with 
chemotherapy in limited disease small cell lung cancer patients
Hipofrakcjonowana konformalna radioterapia skojarzona z chemioterapią u chorych 
na drobnokomórkowego raka płuca w postaci ograniczonej
The study has been conducted within statutory activity of M. Sklodowska-Curie Memorial Cancer Center and Institute 
of Oncology in Warsaw, without additional funding sources
Abstract
Aim: To evaluate the results of hypofractionated conformal radiotherapy (RT) in limited disease small cell lung cancer (LD-SCLC) 
patients, with particular interest in the value of “early” RT, i.e. given before the 3rd chemotherapy (CHT) cycle. 
Material and methods: Outcome of hypofractionated RT (42 Gy, 2.8 Gy/fraction, given over 19–21 days, using “concomitant 
boost” technique — elective volume [39 Gy, 2.6 Gy/fraction] and tumour volumes treated during the same fraction) combined 
with CHT in 100 consecutive LD-SCLC patients, was retrospectively assessed. The outcomes were compared with a previously 
published series of 117 LD-SCLC patients treated in the same institution with hyperfractionated or conventionally fractionated RT. 
Results: Forty-two patients (42%) received “early” RT. Grade 3 NCI CTC acute oesophageal toxicity appeared in 5% of patients. 
There were three treatment-related deaths. Three-year overall survival (OS) rate was 39.4%, median — 24 months in the exa-
mined group vs. 26.0%, and 18 months in historical control, P = 0.02. Three-year OS for 78 patients with completed CHT was 
42.2%, median — 28 months vs. 30%, and 14 months for 22 patients who received ≤ 3 CHT cycles, (P = 0.03). The actuarial 
3-year locoregional failure risk (LRFR) was 34.0% in the examined group vs. 51.0% in the historical control, P = 0.04. Multivariate 
analysis showed a marginally significant correlation between the “early” use of RT and LRFR: RR = 0.43 (95% CI: 0.17–1.04), 
P = 0.06, with no significant impact on OS.
Conclusions: Shorter duration of RT using hypofractionation results in encouraging outcomes and acceptable toxicity. Completion 
of all planned CHT cycles is the most important factor for OS. 
Key words: small cell lung cancer, limited disease, hypofractionated radiotherapy, timing of radiotherapy
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Streszczenie
Cel: Ocena wyników hipofrakcjonowanej konformalnej radioterapii (RT) u chorych na drobnokomórkowego raka płuca w postaci ogra-
niczonej (DRP-LD), z uwzględnieniem wartości „wczesnej” RT, tzn. rozpoczętej przed podaniem trzeciego kursu chemioterapii (CHT). 
Materiał i metody: Przeprowadzono retrospektywną ocenę wyników leczenia 100 kolejnych chorych na DRP-LD, leczonych we-
dług schematu hipofrakcjonowanej RT skojarzonej z CHT: dawka — 42 Gy po 2,8 Gy, w tym 39 Gy po 2,6 Gy na obszar elektywny 
(technika concomitant boost — obszar elektywny i zmiany chorobowe leczone w czasie jednej frakcji), 19–21 dni leczenia. Wyniki 
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leczenia porównano z wynikami grupy historycznej 117 chorych napromienianych w tym samym ośrodku według schematu 
konwencjonalnej lub hiperfrakcjonowanej RT.
Wyniki: „Wczesną” RT otrzymało 42% chorych. Popromienne zapalenie przełyku w stopniu 3 według NCI CTC stwierdzono 
u 5% chorych. Odnotowano trzy zgony związane z leczeniem. Aktualizowany odsetek 3-letnich przeżyć całkowitych (OS) wyniósł 
39,4%, mediana 24 miesiące w grupie badanej v. 26,0% i 18 miesięcy w grupie historycznej, P = 0,02. Trzyletnie OS dla chorych, 
którzy otrzymali ≤ 3 kursy CHT (22 chorych), wyniosło 30,0%, mediana 14 miesięcy v. 42,2% i 28 miesięcy dla 78 chorych, którzy 
otrzymali > 3 kursy CHT, P = 0,03. Aktualizowane 3-letnie ryzyko wznowy miejscowo-regionalnej (LRF) wyniosło 34,0% v. 51,0% 
w grupie historycznej, P = 0,04. Analiza wielowariantowa wykazała trend w kierunku zmniejszenia ryzyka LRF przy zastosowaniu 
„wczesnej” RT: RR = 0,43 (95%CI: 0,17–1,04), P = 0,06. Czas zastosowania RT nie wpływał znamiennie na OS.
Wnioski: Skrócenie leczenia przez zastosowanie hipofrakcjonacji pozwala na uzyskanie dobrych wyników leczenia przy niewielkiej 
toksyczności. Decydujący wpływ na przeżycie chorych ma realizacja całej zaplanowanej CHT. 
Słowa kluczowe: drobnokomórkowy rak płuca, postać ograniczona, radioterapia hipofrakcjonowana, czas rozpoczęcia radioterapii
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Introduction
The value of thoracic radiotherapy (RT) in 
the treatment of limited disease (LD) small-cell 
lung cancer (SCLC) was finally established when 
two meta-analyses showed that it improves ove-
rall survival [1, 2]. However, there is still much 
controversy about timing of RT in relation to 
chemotherapy (CHT), the way of combining these 
two methods, the schedule of RT fractionation, 
the total irradiation dose and the irradiation 
volume. Treatment results may be improved by 
using “early” RT with concurrent CHT [3–6], 
on condition that CHT is delivered as intended 
[7, 8]. Shortening the duration of RT also leads to 
an improvement in treatment results; however, 
accelerated RT is connected with an increased 
early toxicity, mainly radiation oesophagitis [9, 
10]. The best results so far have been obtained 
with the use of “early” accelerated hyperfractiona-
ted RT, i.e. twice-daily treatment with lower dose 
per fraction [10]. However, due to its significant 
toxicity, this schedule should only be considered 
in carefully selected fit patients. The remaining 
patients receive conventionally fractionated 
(i.e. with fraction dose of 1.8–2.0 Gy), prolonged 
(44 days) RT after completion of CHT [11], which 
makes combined treatment significantly longer. 
Moreover, twice-daily irradiation is costly, logi-
stically challenging and usually requires hospi-
talisation, which precludes the adoption of this 
schedule as a standard regimen in most cancer 
centres in the world [12–14]. 
Considerable shortening of the overall treat-
ment time is also achievable by the use of hypo-
fractionated RT, i.e. with higher doses per fraction. 
The results and tolerance of hypofractionated RT 
(40 Gy in 15 fractions) did not differ from conven-
tional RT in 215 patients irradiated in the same 
institution (retrospective data) [15]. However, we 
lack prospective studies on larger cohorts, which 
would concern the application of three-dimen-
sional (3D) conformal hypofractionated RT, using 
contemporary irradiation techniques. So far, such 
a treatment schedule has not been compared with 
conventional RT in a randomised study, and the 
final results of the only randomised prospective 
study that has compared hypofractionated RT 
with accelerated hyperfractionated RT will not be 
available for the next few years [16].
In the present study, we have compared the 
outcomes of 100 consecutive LD-SCLC patients 
treated with definitive hypofractionated RT with 
the outcomes of a historical control group of 117 
patients treated at the same centre with conven-
tional or hyperfractionated RT. The value of the 
shortening of overall treatment time by the use 
of “early” hypofractionated RT has been additio-
nally assessed.
Material and methods
Between 2007 and 2011, in the Department 
of Radiotherapy, Maria Sklodowska-Curie Me-
morial Cancer Centre and Institute of Oncology 
in Warsaw, one hundred consecutive LD-SCLC 
patients received accelerated hypofractiona-
ted RT with curative intent; treatment outco-
mes and toxicity were retrospectively assessed. 
A summary of the characteristics of the patients 
is presented in Table 1.
In all cases the diagnosis of SCLC was confir-
med histopathologically. The staging procedure 
included a complete history, physical examina-
tion, blood tests, bronchoscopy, chest computed 
tomography (CT), CT or ultrasound of the abdo-
men, brain CT or MRI and bone scanning. All 
patients met the following eligibility criteria for 
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Table 1.  Clinical characteristics of the study group (100 
patients) and the historical group (117 patients)
Tabela 1. Charakterystyka grupy badanej (100 chorych)  
i grupy historycznej (117 chorych)
Characteristics Study group
Number  
of patients  
(equals  
percentage)
Historical 
group
Number 
(percent)  
of patients
Gender
Male
Female
52 
48 
73 (62)
44 (38)
Age (years) Median: 59
(range: 41–81) 
Median: 57
(range: 43–78)
Karnofsky performance 
status (KPS)^ [17]
90–100
80 
70
85 
12
3 
116 (99)
1 (<1)
Comorbidity*
Yes
No
73
27
51 (44)
65 (56)
Side
Right
Left
49
51
69 (59.5)
47 (40.5)
Bulky disease#
Yes
No
66
34
70 (60)
47 (40)
Upper mediastinal in-
volvement (groups 1–2)
Yes
No
42
58
23 (20)
94 (80)
N-stage
N0
N1
N2
N3
No exact data
6
6
45
38
5
20 (17)
11 (9)
51 (44)
24 (21)
11 (9)
*comorbidity was defined as a chronic disease requiring long-term drug therapy 
and/or another malignant neoplasm; #Bulky disease was defined as an involve-
ment of three or more lymph node stations or a single lymph node enlargement 
> 3 cm in short axis; ^before radiotherapy
radical RT established at our institution: limited 
stage disease, a Karnofsky performance status 
(KPS) [17] > 70, no contraindications to chest 
RT, and no contraindications to PE (cisplatin + 
etoposide) or KE (carboplatin + etoposide) CHT.
Four cycles of PE or KE CHT at 21-day intervals 
were recommended, but some patients received 
five or six cycles. The CHT cycle that included RT 
was elongated to 28 days. RT was to be included 
after the first or second cycle of CHT, but, due to 
logistical reasons, some patients received RT after 
the third cycle or after the end of all CHT cycles. 
RT was 3D-planned, prescribed to the ICRU 
reference point, and consisted of 42 Gy, 2.8 
Gy/fraction, including total dose to an elective 
volume of 39 Gy (2.6 Gy/fraction), given over 
the course of 3 weeks (19–21 days), 5 times 
a week. “Concomitant boost” technique was used 
— elective volume and tumour volumes were 
treated during the same fraction. 6 MV X pho-
tons from a linear accelerator were used. Clinical 
target volume (CTV) and planning target volume 
(PTV) were determined based on CT, separately 
for elective volume (CTV1 and PTV1) and for 
macroscopic disease (CTV2 and PTV2). CTV1 
included the following: the ipsilateral hilum, 
and nodal stations 7, 4R, 4L, 6, 3A, 2R, 2L, and 
5 for the left side tumours. In the case of “bulky 
mediastinal disease” (i.e. an involvement of more 
than two mediastinal nodal stations or a single 
LN with a short axis diameter ≥ 3 cm), CTV1 was 
additionally enlarged to encompass stations 1R 
and 1L, and supraclavicular areas. CTV2 included 
the gross tumour with a 5 mm margin and the 
whole of the nodal stations with pathologically 
enlarged lymph nodes (i.e. lymph nodes > 1 cm 
in the short-axis view on CT). In the case of 
tumour shrinkage within pulmonary parenchyma 
after CHT, CTV2 encompassed post-CHT tumour 
volume, but lymph node stations were included 
in CTV2 in accordance with pre-chemotherapy 
nodal involvement, even in cases of complete 
response. PTV1 and PTV2 were created by ad-
ding a 1 cm margin to the appropriate CTVs. The 
mean lung dose could not exceed 20 Gy; less than 
35% of the lung volume was to receive more than 
20 Gy. Maximum dose to the spinal cord could not 
exceed 40 Gy. Less than 50% of the heart volume 
could receive more than 40 Gy. The dose to the 
oesophagus had to be kept as low as possible. 
Prophylactic cranial irradiation (PCI) — 
25 Gy in 10 fractions — was offered to patients 
with complete response (CR) or near-complete 
response (nCR), after completion of treatment. 
The following conditions were considered rela-
tive contraindications to PCI: neurodegenerative 
changes, dementia syndrome, alcoholism, epilep-
sy, cerebrovascular diseases and age > 75 years.
The lung, oesophageal and haematological 
toxicity were reported according to the NCI Com-
mon Toxicity Criteria, version 3 (NCI CTC) [18]. 
Moreover, acute lung toxicity was scored using 
the Southwest Oncology Group (SWOG) scale 
[19], whereas late pulmonary, and acute and late 
oesophageal toxicities were reported according to 
the Radiation Therapy Oncology Group (RTOG) 
scale [20].
One month after completion of treatment, 
chest CT was performed to assess response using 
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Table 2.  Treatment characteristics of the study group  
(100 patients) and the historical group (117 patients)
Tabela 2. Porównanie grupy badanej (100 chorych) i grupy 
historycznej (117 chorych) w aspekcie zastoso-
wanego leczenia
Characteristics Study 
group
Number of 
patients 
(equals 
percentage)
Historical 
group
Number 
(percent)  
of patients
Use of PCI
Yes
No
53
47
46 (39)
71 (61)
Type of chemotherapy
PE
KE
PN
CAV
Other (mostly combinations of 
above)
78
19
1
0
2
100 (85)
6 (5)
0
1 (1)
10 (9)*
Number of CHT cycles delivered
≤3
>3
22
78
9 (8)
108 (92)
Timing of RT
Early^
Late‡
42
58
35 (30)†
82 (70)
RT planning
2D
2D elective volume, 3D boost volume
3D
0
0
100
0
61 (52)
56 (48)
Combination of RT and CHT
Concurrent
Alternating
Sequential
RT between 1st and 2nd or 2nd and 3rd 
cycle of CHT (early sequential RT)
RT after CHT
0
0
100
42
58
17 (15)
18 (15)
82 (70)
0
82 (70)
RT dose and fractionation
42 Gy in 15 fractions of 2.8 Gy׳׳ 
(BED = 60 Gy)
39 Gy in 15 fractions of 2.6 Gy (BED 
= 55,4 Gy)
49.8 Gy in 18 fractions׳׳׳ (BED = 
66,4 Gy)
45 Gy b.i.d. of 1.5 Gy (BED = 58 Gy)
56 Gy of 2 Gy (20Gy+20Gy+16Gy₫) 
(BED = 56 Gy)
44-60 Gy of 2 Gy, median 56 Gy 
(median BED = 60,2 Gy; range 51,4 
Gy – 63,6 Gy)
98
1
1
0
0
0
0
0
0
17 (15)
18 (15)
82 (70)
*two patients did not receive platinum-based chemotherapy; ^ “early” radiotherapy 
was defined as started before the 3rd cycle of chemotherapy; ‡“late” radiotherapy was 
defined as started after the 3rd cycle of chemotherapy; †including 17 patients (15%) 
with hiperfractionated radiotherapy given concurrently with chemotherapy; 18 patients 
(15%) — alternating radiochemotherapy with conventionally fractionated radiotherapy; 
׳׳with 39 Gy, 2.6 Gy/fraction to elective volume; ׳׳׳42 Gy, 2.8 Gy/fraction + 3 additional 
fractions, each of 2,6 Gy; ₫alternating radiochemotherapy; PCI — prophylactic cranial 
irradiation; RT — radiotherapy; CHT — chemotherapy; 2D — two-dimensional ra-
diotherapy planning; 3D — three-dimensional radiotherapy planning; b.i.d. — twice 
daily; PE — Cisplatin + Etoposide; KE — Carboplatin + Etoposide; PN — Cisplatin + 
Vinorelbine; CAV — Cyclophosphamide +Doksorubicin +Vincristine; BED — biologi-
cally effective dose, calculation method given in „Material and methods”
RECIST (Response Evaluation Criteria in Solid 
Tumours) criteria [21]. The additional category of 
nCR was introduced, defined as residual disease 
visualised on the chest CT, which could not be 
visible on a chest X-ray. Follow-up examinations 
were carried out every 3 months.
The historical control group included 117 
LD-SCLC patients, who received conventionally 
fractionated or hyperfractionated RT in the De-
partment of Radiotherapy, Maria Sklodowska-
Curie Memorial Cancer Centre and Institute of 
Oncology in Warsaw between 1997 and 2006 [22]. 
Characteristics of the patients and the treatment 
applied are presented in Tables 1 and 2.
To compare the effect of different fractiona-
tion schedules, the biologically effective dose 
(BED) formula, proposed by Fowler [23], was used:
BED = nd[1 + d/(a/b)] – ln2(T – Tk)
where  n – number of fractions, d – dose 
per fraction; T — total irradiation time; a/b — 
radiobiological parameter used to describe the 
response to fractionation (for SCLC = 10 [24]); 
Tk — time of onset of accelerated tumour repo-
pulation (for SCLC = 28 days [24]). 
Three-year overall survival (OS) and progres-
sion-free survival (PFS) rates were assessed using 
the Kaplan-Meier method from the start of CHT, 
as well as the 3-year actuarial locoregional failure 
risk (LRFR), and the actuarial risk of distant meta-
stases (DM) and brain metastases (BM). Univariate 
(log-rank) and multivariate (Cox regression model) 
analyses were used to evaluate the influence of 
the RT timing (“early” vs. “late”) and other clini-
cal variables, such as: age (< 65 vs. ≥ 65 years), 
gender, KPS (70-80 vs. 90–100), the presence of 
“bulky” mediastinal disease, the use of PCI and 
the number of CHT cycles delivered (≤ 3 vs. >3) 
on the treatment outcomes. Only predictors with 
P-value < 0.20 in univariate analysis were inc-
luded in multivariate analysis. The impact of RT 
timing on the delivery of RT according to the pro-
tocol (i.e. treatment breaks) and CHT compliance 
was determined using the Mann-Whitney U test. 
The Wilcoxon test for age and the nonparametric 
Mann-Whitney U test for the remaining parame-
ters (gender, KPS, the presence of “bulky disease”, 
the use of PCI, the number of CHT cycles, type 
of CHT: platinum vs. non-platinum based, RT 
timing, BED of RT) were used to determine the 
distribution of patient characteristics within the 
compared groups. The log-rank test was used to 
analyse differences in OS, PFS and LRFR between 
the groups. The Chi-squared test was used to 
compare RT-induced toxicity between groups. 
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A P value of less than 0.05 was considered stati-
stically significant. IBM SPSS Statistics v. 20 was 
used for statistical analysis.
“Early” RT was defined as being given before 
the third cycle of CHT. LRF was defined as tumo-
ur progression within the lung and/or regional 
nodal failure. 
Results
The median follow up for living patients was 
30 months (range 11–17). 
“Early” RT was administered in 42 patients 
(42%), and the remaining 58 patients (58%) re-
ceived “late” RT. Sixteen patients (16%) required 
RT breaks, in all cases because of haematological 
toxicity. The median duration of a break was 5 days 
(range: 2–17). Ten patients with break received 
“early” RT (24%), and six patients received “late” 
RT (10%); P = 0.15. Seventy-eight patients (78%) 
received all planned cycles of CHT: 67% of patients 
in the “early” RT group and 86% of patients in 
the “late” RT group, P =  0.03. The reasons for 
not completing all planned cycles of CHT in the 
groups with “early” and “late” RT are presented 
in Table 3. Haematological toxicity was the reason 
for stop CHT before completion of four planned 
cycles in 8 (19%) patients with  “early” RT, and in 7 
(12%) patients with “late” RT. Non-haematological 
toxicity (i.e. acute oesophageal toxicity) was the 
reason for discontinuation of systemic treatment 
in 2 patients (5%) with “early” RT, whereas in the 
group with “late” RT, non-haematological toxicity 
did not hinder the continuation of CHT. Fifty-two 
patients (52%) received PCI.
There was no grade ≥ 3 acute or late pulmonary 
toxicity observed. Grade 3 (NCI CTC) acute esopha-
geal toxicity was recorded in 5 patients (5%), none of 
them required nasogastric tube insertion for feeding 
— according to RTOG scale, this was scored as grade 2. 
We did not observe grade ≥ 3 late oesophageal toxi-
city. Grade 3–4 neutropenia and thrombocytopenia 
were found in 41 patients (41%) and in 11 patients 
(11%), respectively; grade 3 anaemia was seen in 
10 patients (10%). There were three treatment-rela-
ted deaths (3%). Treatment toxicity according to the 
timing of RT is presented in Table 4.
After completion of treatment, the CR, nCR, 
partial response and disease stabilization rates 
were 59%, 24%, 10% and 1%, respectively. In 
3 patients (3%) disease progression outside the 
chest occurred during treatment. Treatment re-
sponse could not be determined in 3 patients (3%) 
who had died prior to completion of treatment.
Three-year OS rate was 39.4%, and median 
survival time (MST) was 24 months (Fig. 1). In 
the group with “early” RT, 3-year OS was 40.0%, 
MST was 27 months, and in the group with “late” 
3-year RT OS was 38.7% and MST 22 months, 
P = 0.40. Univariate analysis found the number 
of CHT cycles delivered to be the only signifi-
cant prognostic factor for OS: 3-year OS rate for 
patients with completed CHT (78 patients) was 
42.2%, vs. 30% for 22 patients who received 3 or 
less cycles of CHT, with median survival of 28 
and 14 months, respectively (P = 0.03) (Fig. 2). 
Multivariate analysis showed a marginally signi-
ficant correlation between the fail of delivery of 
all planned cycles of CHT and OS rates: relative 
risk (RR) = 1.79 (95% CI: 0.98–3.29), P = 0.059. 
Table 3.  Reasons for not completing all four courses of chemotherapy according to the timing of radiotherapy
Tabela 3.  Przyczyny przedwczesnego zakończenia chemioterapii (tzn. podania mniej niż planowane 4 kursy) w grupie  
chorych z radioterapią „wczesną” i „późną”
Reason ”Early” radiotherapy  
n = 42
„Late” radiotherapy  
n = 58
Number of patients Percent of patients Number of patients Percent of patients
Performance status, comorbidities 2 5 1 2
Hematologic toxicities 8 19 7 12
Non-hematologic toxicities:
   renal 1 2 0 0
   acute esophageal 2 5 0 0
   acute pulmonary 1 2 0 0
Total 14 33 8 14
„Early” radiotherapy was defined as started before the 3rd cycle of chemotherapy; „late” radiotherapy was defined as started after the 3rd cycle of chemotherapy.
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Table 4.  Treatment toxicity according to the timing of radiotherapy
Tabela 4.  Częstość występowania toksyczności leczenia w zależności od czasu rozpoczęcia radioterapii
Treatment  
toxicity  
and RT 
timing
Toxicity grade* P-value#
BD/ND 0 1 2 3 4 5
Number (percent) of patients
Neutropenia 0.0001
Early RT^ 8 (19) 5 (12) 1 (2.5) 2 (4.5) 10 (24) 15 (35.5) 1 (2.5)
Late RT+ 11 (19) 14 (24) 11 (19) 6 (10.5) 6 (10.5) 10 (17) 0 (0)
Thrombocytopenia 0.03
Early RT^ 8 (19) 11 (26.5) 11 (26.5) 7 (16.5) 4 (9) 1 (2.5) 0
Late RT+ 9 (15.5) 30 (51.5) 11 (19) 2 (3.5) 2 (3.5) 4 (7) 0
Anaemia
0.15Early RT^ 8 (19) 5 (12) 16 (38) 12 (28.5) 1 (2.5) 0 0
Late RT+ 9 (15.5) 4 (7) 19 (32.5) 17 (29.5) 9 (15.5) 0 0
Acute esophageal toxicity
0.74Early RT^ 0 15 (35.5) 15 (35.5) 8 (19) 4 (9.5) 0 0
Late RT+ 0 19 (32.5) 27 (47) 11 (19) 1 (1.5) 0 0
Late esophageal toxicity
0.50Early RT^ 3/5 (7.5/12) 31 (73.5) 2 (4.5) 1 (2.5) 0 0 0
Late RT+ 3/9 (5/15.5) 44 (76) 0 2 (3.5) 0 0 0
Acute pulmonary toxicity
0.72Early RT^ 0 40 (95) 1 (2.5) 1 (2.5) 0 0 1 (2.5)
Late RT+ 0 52 (89.5) 5 (9) 1 (1.5) 0 0 1 (1.5)
Late pulmonary toxicity
0.18Early RT^ 3/5 (7.5/12) 28 (66.5) 2 (4.5) 4 (9.5) 0 0 0
Late RT+ 2/9 (3.5/15.5) 36 (62.5) 10 (17) 1 (1.5) 0 0 0
*according to NCI Common Toxicity Criteria, version 3, 2006 [18]; #estimated with the use of the chi-square test for all grades of toxicity; ^ radiotherapy started before 
the 3rd cycle of chemotherapy (42 chorych); +radiotherapy started after the 3rd cycle of chemotherapy (58 chorych); p — statistical significance; RT — radiotherapy; 
BD — no data; ND — not applicable (4 patients had died within 6 months from the start of radiotherapy, before the late toxicity could occurred; in 10 patients late 
toxicity was not assessed, due to locoregional failure)
No statistically significant correlation between OS 
and the remaining analysed factors was found.
Three-year PFS rate was 31.3%, median PFS 
was 14 months. Univariate and multivariate 
analysis did not reveal any statistically significant 
correlation between PFS and the analysed factors. 
The actuarial LRFR at three years was 34.0%; 
3-year LRFR was 28.4% and 45.1% in the group 
with “early” and “late” RT, respectively, P = 0.09 
(Fig. 3). Multivariate analysis showed a marginally 
significant correlation between the “early” use of RT 
and LRFR: RR = 0.43 (95% CI: 0.17–1.04), P = 0.06. 
The actuarial 3-year DM risk was 54.6%. Per-
formance status was statistically significantly cor-
related with the risk of DM in univariate analysis. 
In patients with KPS 90-100, the actuarial 3-year 
DM risk was 51.3%, median — 31 months; in pa-
tients with KPS 70–80 — 74.3% and 12 months, 
respectively, P = 0.03. In multivariate analysis this 
factor was not statistically significant.
BM was the first site of recurrence in 17 pa-
tients (17%); of these, 11 did not receive PCI. The 
actuarial risk of BM as the first site of recurrence 
at three years was 29.1% in the whole group of pa-
tients. This rate was 22.9% and 38.6% in patients 
with and without PCI, respectively, P = 0.04. 
Performance status was significantly better 
in the historical group, P < 0.001. The number 
of CHT cycles received (≤ 3 vs. > 3) was signifi-
cantly lower in the study group (P = 0.001). PCI 
administration was significantly less frequent 
in the historical group (P = 0.04). There were 
no statistically significant differences between 
the two groups regarding the distribution of the 
remaining analysed clinical variables potentially 
influencing the outcomes.
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Treatment toxicity did not differ significantly 
between the study group and historical controls 
(Table 5).
Median follow up for the living patients in 
the historical group was 33 months (range 13–80). 
In this group, the 3-year PFS rate was 15% 
and median PFS was 10 months, whereas in the 
study group it was 31.3% and 14 months, respec-
tively, P < 0.001.
In the historical group, the 3-year OS rate 
was 26% and MST was 18 months, whereas in 
the study group it was 39.4% and 24 months, 
respectively, P = 0.02 (Fig. 4).
The actuarial LRFR at 3-years was 51% in the 
historical group and 34.0% in the study group, 
P = 0.04 (Fig. 5).
DM was the most common pattern of failure 
in both groups. The rate of BM as the first site of 
failure was 18% in the historical group and 17% 
in the study group.
Discussion
Results of our study show that accelerated 
hypofractionated RT is a treatment of acceptable 
toxicity and effectiveness. Changing RT practice 
Figure 1. Overall survival in 100 study patients
Rycina 1. Odsetek przeżyć całkowitych w grupie badanej (100 chorych)
Figure 2. Overall survival according to the number of chemotherapy 
cycles delivered
Rycina 2. Odsetki przeżyć całkowitych w zależności od podania 
wszystkich zaplanowanych kursów chemioterapii
Figure 3. Locoregional failure risk according to the radiotherapy tim-
ing: „early” radiotherapy, i.e. started before the 3rd cycle of chemother-
apy (42 patients) v. „late” radiotherapy, i.e. started after the 3rd cycle 
of chemotherapy (58 patients)
Rycina 3. Ryzyko wystąpienia wznowy miejscowo-regionalnej w za-
leżności od czasu zastosowania radioterapii — radioterapia „wcze-
sna”, tj. rozpoczęta przed podaniem trzeciego kursu chemioterapii 
(42 chorych) v. „późna”, tj. rozpoczęta po podaniu trzeciego kursu 
chemioterapii lub po zakończeniu chemioterapii (58 chorych) 
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Table 5. Treatment toxicity in the study group and in the historical group
Tabela 5. Częstość występowania toksyczności leczenia w grupach badanej i historycznej
Treatment toxicity Toxicity grade P-value#
2 3 4
Number (percent) of patients
Acute esophageal toxicity‡ 0.64
Study group 24 (24) 0* 0
Historical group 18 (15) 2 (2) 0
Late esophageal toxicity‡ BD
Study group 3 (3) 0 0
Historical group BD BD BD
Acute pulmonary toxicity^ 0.61
Study group 2 (2) 0 0
Historical group 7 (6) 0 0
Late pulmonary toxicity‡ 0.14
Study group 5 (5) 0 0
Historical group 12 (10) 1 (< 1) 0
Treatment-related deaths 0.37
Study group 3 (3)
Historical group 1 (< 1)
^according to the Southwest Oncology Group (SWOG) scale [19]; ‡according to the Radiation Therapy Oncology Group (RTOG) scale [20]; #estimated with the use 
of the chi-square test for all grades of toxicity; *according to the NCI Common Toxicity Criteria scale, version 3, 2006 [18], grade 3 esophageal toxicity was recorded 
in 5 patients, but it was assessed as grade 2 according to the RTOG scale; BD — no data; P — statistical significance
Figure 4: Overall survival in the study group (100 patients) and in the 
historical group (117 patients)
Rycina 4. Odsetki przeżyć całkowitych w grupach: badanej 
(100 chorych) i historycznej (117 chorych)
Figure 5. Locoregional failure risk in the study group (100 patients) 
and in the historical group (117 patients)
Rycina 5. Ryzyko wystąpienia wznowy miejscowo-regionalnej 
w grupach: badanej (100 chorych) i historycznej (117 chorych)
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from previously used RT regimens to trial-defi-
ned hypofractionation had a positive impact on 
the outcomes of LD-SCLC patients treated with 
RT in the Department of Radiotherapy, Maria 
Sklodowska-Curie Memorial Cancer Centre and 
Institute of Oncology in Warsaw. A statistically 
significant difference was found in OS and PFS 
(P = 0.02 and P < 0.001, respectively), and LRFR 
was lower in the study group (P = 0.04). These 
results have been obtained without enhance-
ment of toxicity, which additionally increases 
the value of this method of treatment. However, 
the retrospective nature of the study and lack of 
uniform RT schedule in the historical group limits 
our conclusions. Moreover, the comparison with 
historical control is a limitation itself as it is not 
possible to exclude the impact on outcome of 
some changes in the pattern of practice regarding 
RT and CHT, which could have taken place during 
10 years (1997–2007). For instance, some patients 
in the historical group underwent two-dimensio-
nally (2D) planned RT. However, in the majority 
of the published studies of thoracic irradiation 
in SCLC-LD patients, RT was based entirely on 
conventional 2D treatment planning; and the best 
treatment results so far were obtained in the era 
of 2D RT [10]. Furthermore, the range of BEDs 
in both compared groups was within currently 
recommended dose limits used in the treatment 
of LD-SCLC. The application of PCI differed 
significantly between the two examined groups; 
however, similar frequencies of BM were found 
in both groups. The better performance status 
of patients in the historical cohort may suggest 
more strict eligibility criteria for definitive RT 
in this group. The study group consisted of 100 
consecutive patients with KPS ≥ 70, so selection 
criteria was not so rigorous — which is an ad-
ditional advantage, as the presented RT schedule 
can be used in a wider population of patients. 
A negative consequence of less strict qualification 
criteria in the study group can be the lower pro-
portion of patients who completed the planned 
CHT, compared to the historical control group; 
proportions of patients who received > 3 CHT 
cycles were 78% and 92% in the study group and 
in the historical cohort, respectively; P = 0.001. 
Weight loss is an important parameter that could 
influence the outcomes, but the data on weight 
loss in the study group were incomplete, and 
were omitted in the analyses, which also limits 
the conclusions.
The obtained results and data from the litera-
ture may suggest that the efficacy of hypofractio-
nated RT (particularly the “early” hypofractiona-
ted RT) is similar to that of hyperfractionated RT, 
on condition that the planned CHT is completed. 
In a randomised study conducted in Canada [4], 
which compared “early” vs. “late” hypofractio-
nated RT (40 Gy in 15 fractions), MST in the 
“early” arm was 21.2 months and 5-year OS rate 
was 20%, whereas in the study by Turrisi et al. 
[10], in the arm with hyperfractionated RT these 
values were 23 months and 26%, respectively. In 
the retrospective study by Xia et al. [25] half of 
the patients received hyperfractionated RT (56 
Gy in 40 fractions, 1.4 Gy twice daily), and the 
other half received hypofractionated RT (55 Gy in 
22 fractions, 2.5 Gy/fraction). There was no sta-
tistically significant survival difference between 
both groups, and MST was 27 months. Another 
retrospective study [26] reported the outcomes 
of 227 patients who underwent mainly mild hy-
pofractionated irradiation (40 Gy in 15 fractions, 
2.67/fraction): MST was 22 months, and 5-year 
OS rate was 25%. 
Attempts to modify and intensify the radio-
chemotherapy regimens used in LD-SCLC have 
led to improvement in survival in some studies 
[3, 4, 6, 10, 27]; however, improvement in loco-
regional control still remains a therapeutic chal-
lenge. In the study by Turrisi et al. [10] the LRF 
rate in the hyperfractionated arm was 36%, and 
in the study by Bonner et al. [28, 29] an LRF rate 
of 34% was found in both study arms. This rate 
was slightly lower in the present study (27%), 
but the significantly shorter follow-up period 
should be taken into consideration. The actuarial 
3-year LRFR of 34% is comparable to that obta-
ined in other studies [3, 26, 28, 29]. However, the 
relatively high LRFR in patients with “late” RT 
(45.1% at 3 years) may suggest that the applied 
total dose is too low in this group and should be 
adjusted. The BED of the presented RT schedule 
is 60 Gy, thus being in the range of the currently 
recommended doses applied in the treatment of 
LD-SCLC; however, it would be valuable to modi-
fy this schedule in order to increase the biological 
dose of radiation.
In our study, reduced LRFR with “early” 
RT did not translate into a meaningful survival 
advantage, which may imply that DM remain the 
major problem. This may result from the differen-
ce in the proportion of patients who received at 
least four cycles of CHT, which was statistically 
significant, favouring the “late” over the “early” 
RT group (86% and 67% of patients, respectively, 
P = 0.033). A marginally significant correlation 
between the fail of delivery of all planned cycles 
of CHT and OS rates was found: RR = 1.79 (95% 
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CI: 0.98–3.29), P = 0.059. The results of other stu-
dies also indicate such a relationship. In a British 
randomised study comparing “early” and “late” 
hypofractionated RT (40 Gy in 15 fractions), CHT 
in the “early” arm was completed as intended in 
69% of patients, whereas in the “late” arm it was 
completed in 80%, P = 0.03 [8]. The probability 
of OS did not differ between the arms, despite 
the improvement in locoregional control with 
the use of “early” RT (LRF rate of 26% vs. 37% in 
“early” and “late” arms, respectively; P = 0.03). 
The authors conducted a meta-analysis of eight 
trials and concluded that the optimal delivery 
of CHT is indispensably necessary to derive any 
benefit from the “early” use of RT [8]. The newest 
meta-analysis confirms the key role of completion 
of all planned cycles of CHT [7]. “Early” RT re-
sulted in an improvement in OS only in trials 
where the “early” and “late” arms showed similar 
CHT compliance (HR = 0.79; 95% CI: 0.69–0.91); 
whereas in the trials where the difference in CHT 
compliance was ≥ 10% between arms, survival 
was worse with “early” RT (HR = 1.19; 95% 
CI: 1.05–1.34) [7]. In the present study we have 
shown an acceptable toxicity of “early” RT, but 
the difference between the “early” and “late” 
groups in the number of CHT cycles delivered 
warrants caution while interpreting the results. 
An additional limitation of our study is the lack of 
precise data concerning the use of chemotherapy, 
especially the dosages of the cytostatics given to 
the patients.
Similarly as in the study by Spiro et al. [8], 
in the present study it is also difficult to estimate 
explicitly, which factors were the main reasons 
for the disproportion in the CHT compliance. 
However, it is important to emphasise the limi-
tations of the conclusions drawn from the lack of 
randomisation and limited number of patients. 
Moreover, the groups of patients with “early” 
and “late” RT were distinguished retrospectively, 
which also hinders interpretation.
Conclusions
Accelerated, hypofractionated RT in combi-
nation with platinum-based CHT is a treatment of 
acceptable toxicity and effectiveness in LD-SCLC 
patients. Overall survival was not significantly 
affected by the timing of RT, although the use of 
“early” RT may offer better locoregional disease 
control. Completion of all planned cycles of CHT 
is the most important factor for overall survival. 
The value of hypofractionated radiotherapy sho-
uld be confirmed in a randomised trial comparing 
this treatment schedule with hyperfractionated 
RT — the current “gold standard” in treatment 
of LD-SCLC. 
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